{"disease":{"id":"non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression-tumor-proportion-score-tps-50-as-monotherapy-pembrolizumab-in-combination-with-pemetrexed-and-platinum-pemetrexed-platinum-in-patients-with-a-pd-l1-tps-1-as-determined-by-an-fda-approved-test.md","name":"non small cell lung cancer nsclc with high pd l1 expression tumor proportion score tps 50 as monotherapy pembrolizumab in combination with pemetrexed and platinum pemetrexed platinum in patients with a pd l1 tps 1 as determined by an fda approved test.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}